entertainment -WSS

entertainment

author：Wikipedia 2025-08-19 15:01:40 - browse：15

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： A solution to the after

entertainment

WSS

Alabama frozen embryo ruling has major implications for IVF clinics

European regulators consider appeal over Amylyx ALS drug

The Harvard botanist who searched for psychedelics in the Amazon

Alabama frozen embryo ruling has major implications for IVF clinics

R1 RCM gets $5.8 billion buyout offer from private equity firm

How should state employee insurance handle Wegovy?

Wikipedia

entertainment

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Ed Silverman on new gene therapies, biosimilars, coffee, and more

United colonoscopy coverage change 'may cost lives,' doctors say

Better Therapeutics data on benefit with GLP

United colonoscopy coverage change 'may cost lives,' doctors say

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

After affirmative action ruling, medical educators look to 'holistic review'

Alabama frozen embryo ruling has major implications for IVF clinics

As demand for Covid shots wanes, Moderna seeks its next success

Wellcome Trust names Røttingen as its new CEO

explore

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

R1 RCM gets $5.8 billion buyout offer from private equity firm

R1 RCM gets $5.8 billion buyout offer from private equity firm

Readout LOUD podcast: Merger Mondays, Ozempic panic

A solution to the after

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

focus

entertainment

knowledge

Wikipedia